69 Results for "

PD-1 signaling

" in MedChemExpress (MCE) Product Catalog:
Products (69)

69 Results for "PD-1 signaling" in MCE Product Catalog:

20
20 Publications Verification
Cat. No.: HY-P99145

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P1812
CAS No.: 1353563-85-5
Synonyms: NP-12
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-12964
CAS No.: 1239875-86-5
Purity:  99.32%
Target:  

TAM Receptor

Research Areas:  

Cancer

SGI-7079 is a selective, ATP-competitive, orally active inhibitor of the receptor tyrosine kinase Axl. SGI-7079 blocks Axl-mediated signaling pathways such as NF-κB activation and MMP-9 expression, thereby inhibiting tumor cell proliferation, migration and invasion. SGI-7079 is mainly used in the research of malignant tumors such as inflammatory breast cancer and bladder cancer, as well as in combination with immunization (used in combination with PD-1 therapy)[1][2][3].
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P1812A
Synonyms: NP-12 TFA
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W342604
CAS No.: 5699-41-2
Synonyms: NAP
N-Acetylputrescine is a polyamine metabolite that regulates cell proliferation and signal transduction mainly by participating in polyamine acetylation modification. N-Acetylputrescine may reduce the positive charge of polyamines, affect protein-nucleic acid interactions, and promote cell growth. The concentration changes of N-Acetylputrescine can help disease diagnosis (such as early screening and efficacy evaluation of lung cancer) and microbial cell wall structure research. N-Acetylputrescine can be used as a potential biomarker for the progression of squamous cell carcinoma of the lung (SCCL) and Parkinson's disease (PD) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-113100
CAS No.: 18233-70-0
Purity:  ≥99.0%
N-Acetylputrescine hydrochloride is a polyamine metabolite that regulates cell proliferation and signal transduction mainly by participating in polyamine acetylation modification. N-Acetylputrescine hydrochloride may reduce the positive charge of polyamines, affect protein-nucleic acid interactions, and promote cell growth. The concentration changes of N-Acetylputrescine hydrochloride can help disease diagnosis (such as early screening and efficacy evaluation of lung cancer) and microbial cell wall structure research. N-Acetylputrescine hydrochloride can be used as a potential biomarker for the progression of squamous cell carcinoma of the lung (SCCL) and Parkinson's disease (PD) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0819
CAS No.: 89412-79-3
Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma .
loading...
    loading...
Cat. No.: HY-P991628
Synonyms: PF-08634404

Target:  

PD-1/PD-L1 VEGFR

Research Areas:  

Cancer

SSGJ-707 (PF-08634404) is a bispecific antibody targeting VEGF and PD-1. SSGJ-707 exerts dual anti-tumor effects by neutralizing VEGF and blocking the PD-1 signaling pathway. SSGJ-707 can be combined with platinum-based chemotherapy to inhibit advanced non-small cell lung cancer (NSCLC), and its inhibitory effect is not limited by PD-L1 expression levels. In the HARMONi-2 trial, the objective response rate of SSGJ-707 correlates with the PD-L1 tumor proportion score, and the incidence of grade ≥3 adverse events is comparable to that of Inetetamab (HY-P99969). SSGJ-707 is being extensively investigated for a variety of malignancies including advanced NSCLC, colorectal cancer and small cell lung cancer .
loading...
    loading...
Cat. No.: HY-P991621
Synonyms: EOS-215
Target:  

TREM receptor

Research Areas:  

Cancer

EOS006215 (EOS-215) is a humanized monoclonal antibody targeting TREM-2. EOS006215 competes with TREM2 ligands, prevents TREM2 multimerization, and blocks downstream signaling. EOS006215 inhibits efferocytosis, reprograms transcriptomic profiles of monocyte-derived macrophages, alters metabolism and immune response genes, and increases pro-inflammatory marker secretion. EOS006215 reduces metastasis burden, delays tumor growth, and reprograms the tumor microenvironment to overcome anti-PD-1 resistance. EOS006215 can be used for the research of triple negative breast cancer and colorectal cancer .
loading...
    loading...
Cat. No.: HY-P991149
CAS No.: 2966936-23-0
Synonyms: YH32367; ABL105

Target:  

TNF Receptor

Research Areas:  

Cancer

Nesfrotamig (YH32367; ABL105) is a bispecific activator targeting HER2 and 4-1BB. The Kd values of Nesfrotamig for human HER2 and human 4-1BB are 0.48 nM and 3.36 nM, respectively. By blocking tumor cell growth signals, activating HER2-dependent local 4-1BB in tumors to maintain T cell survival, and inducing NK cell-mediated antibody-dependent cellular cytotoxicity, Nesfrotamig enhances the cytotoxicity and tumor infiltration ability of immune cells. Nesfrotamig promotes the generation of tumor-specific memory T cells, drives T cell-mediated tumor lysis, exhibits significant anti-tumor efficacy against both HER2-positive and HER2-low-expressing tumors, and shows synergistic activity when combined with anti-PD-1 antibodies. In cynomolgus monkey studies, Nesfrotamig demonstrates good safety and is suitable for research related to HER2-positive and HER2-low-expressing tumors .
loading...
    loading...
Cat. No.: HY-P5005
CAS No.: 125093-93-8
Target:  

CMV PD-1/PD-L1

VIPhyb is a vasoactive intestinal polypeptide (VIP) receptor antagonist. VIPhyb can inhibit VIP signaling, increase T-cell immunity and downregulate PD1. VIPhyb can inhibit cancer cell proliferation. VIPhyb can reduce inflammatory cytokine expression. VIPhyb can enhance viral clearance. VIPhyb can be used for the researches of cancer, infection and inflammation and immunology, such as non-small cell lung cancer (NSCLC), cytomegalovirus infection and colitis .
loading...
    loading...
Cat. No.: HY-N3431
CAS No.: 20196-89-8
Kaempferol-7-O-rhamnoside is a PD-1/PD-L1 inhibitor and farnesoid X receptor (FXR) agonist. Kaempferol-7-O-rhamnoside demonstrates cardioprotective potential targeting the AMPKα1 signaling pathway. Kaempferol-7-O-rhamnoside significantly upregulates the mRNA expression of AMPKα1 in H9c2 cardiomyocytes. Kaempferol-7-O-rhamnoside reverses APAP-induced reduction of glutathione (GSH) content and increase of ROS production in L02 cells. Kaempferol-7-O-rhamnoside has the potential for heart failure .
loading...
    loading...
Cat. No.: HY-P99573
CAS No.: 2245725-04-4
Synonyms: MGD-013

Target:  

LAG-3

Research Areas:  

Inflammation/Immunology Cancer

Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .
loading...
    loading...
Cat. No.: HY-P9996
CAS No.: 2445259-99-2
Synonyms: LY3434172; IBI-318

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Reozalimab (LY3434172; IBI-318) is an IgG1 monoclonal antibody targeting PD-1/PD-L1, with an IC50 of 2.27 nM and an EC50 of 0.080 nM against human PD-1, as well as an IC50 of 0.75 nM and an EC50 of 0.455 nM against human PD-L1. Reozalimab blocks the binding of PD-1 to PD-L1/PD-L2, as well as the binding of PD-L1 to PD-1/CD80, thereby inhibiting the inhibitory signal transduction of the PD-1 pathway. Reozalimab enhances the functional activation of T cells and induces anti-tumor activity in mouse tumor models reconstituted with human immune cells. Reozalimab can be used in research related to cancers such as non-small cell lung cancer and ovarian cancer .
loading...
    loading...
Cat. No.: HY-P99884
CAS No.: 2206792-50-7
Synonyms: PF-06801591

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Sasanlimab is a humanized IgG4 isotype anti-PD-1 antibody. Sasanlimab blocks PD-1 interaction with PD-L1/PD-L2, reverses PD-1-mediated inhibitory T-cell signaling, augments T-cell proliferation and cytokine production. Sasanlimab inhibits colon adenocarcinoma tumor growth, and accelerates graft-versus-host disease incidence via enhanced T-cell activity. Sasanlimab can be used for the research of cancer, such as bladder cancer and colon adenocarcinoma .
loading...
    loading...
Cat. No.: HY-153598
CAS No.: 2782022-40-4
Research Areas:  

Inflammation/Immunology Cancer

LD4172 is a selective RIPK1 PROTAC degrader with a Ki of 4.8 nM. LD4172 induces RIPK1 protein degradation via ternary complex formation with RIPK1 and VHL E3 ligase, driving ubiquitination and proteasomal breakdown. LD4172 abrogates TNF-induced classical NF-κB signaling in TRAF2-deficient cells, impairing IκBα phosphorylation and degradation, and reducing IL-8 production. LD4172 induces apoptosis and immunogenic cell death in tumor cells, enhances tumor-infiltrating lymphocyte responses, and sensitizes tumors to anti-PD1 therapy. LD4172 acts as a chemical probe for investigating RIPK1 scaffolding functions. LD4172 can be used for the research of melanoma, colon cancer .
loading...
    loading...
Cat. No.: HY-P99145A

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG1. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) contains no Fc mutations just as the original rat IgG2b antibody does not. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) can be used for the research of cancer.
loading...
    loading...
Cat. No.: HY-P991740

Research Areas:  

Cancer

IBI-363 is a PD-1/IL-2 bispecific antibody with functions of blocking the PD-1/PD-L1 pathway and activating the IL-2 pathway. The IL-2 arm of IBI-363 retains affinity for IL-2Rα but attenuates binding ability to IL-2Rβ and IL-2Rγ to reduce toxicity. The PD-1 binding arm of IBI-363 enables PD-1 blockade and selective delivery of IL-2. IBI-363 can be used in cancer research, such as non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-P99895
CAS No.: 2417124-95-7

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .
loading...
    loading...
Cat. No.: HY-P10950A
Target:  

PD-1/PD-L1 Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

PD-L1 inhibitory peptide TFA is an inhibitor targeting the PD-1/PD-L1 interaction. PD-L1 inhibitory peptide TFA inhibits the PD-1-mediated apoptosis signaling pathway, maintains the survival and activity of T cells, activates the anti-tumor effect of cytotoxic T lymphocytes, and significantly improves the survival rate of mice in fungal sepsis models. PD-L1 inhibitory peptide TFA can be used for research on sepsis, breast cancer and other related diseases, as well as immunotherapy .
loading...
    loading...